Placebo (ziltivekimab)

DRUG4 trials

Sponsors

Novo Nordisk A/S, Novo Nordisk A/S, ECRI-trials B.V.

Conditions

Acute myocardial infarctionAtherosclerotic cardiovascular diseaseCardiovascular RiskChronic Kidney DiseaseHeart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.Inflammationchronic kidney disease and systemic inflammation

Phase 2

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

CompletedNCT04626505

Novo Nordisk A/SCardiovascular Risk, Chronic Kidney Disease, Inflammation

Start: 2020-10-22End: 2021-09-28Updated: 2026-05-06

Phase 3

HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Active, not recruitingCTIS2022-501939-16-00

Novo Nordisk A/SHeart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.

Start: 2023-05-09Target: 2219Updated: 2026-01-26

ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Active, not recruitingCTIS2023-506926-35-00

Novo Nordisk A/SAtherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Start: 2021-09-24Target: 2335Updated: 2025-11-10

Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study

Not yet recruitingCTIS2024-520364-34-00

Novo Nordisk A/S, ECRI-trials B.V.Acute myocardial infarction

Target: 249Updated: 2026-01-19

Related Papers

Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial

Journal of Cardiology2023-05-1941 citations